Factors Associated with Gastric Signet Ring Cell Carcinoma in CDH1 Pathogenic Variant Carriers: Report from the GASTRIC Consortium

Gastrointestinal Cancer

Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls

Gut

Lobo S, Dias A, Pedro AM, Ferreira M, Pinto-Oliveira A, São José C, Herrera-Mullar J, Pinto N, Colas C, Hüneburg R, Nattermann J, Boussemart L, van Hest LP, Moreira L, Horton C, Farengo Clark D, Tinschert S, Golmard L, Spier I, López-Fernández A, Oliveira D, Svrcek M, Bourgoin P, Coulet F, Delhomelle H, Davis J, Zäncker B, Lazaro C, Guerra J, Almeida ML, Carrera S, Patiño A, Gundlach P, Laszkowska M, Strong VE, Teixeira MR, Schrader I, Steinke-Lange V, Gullo I, Sousa S, Batista M, Aretz S, Balmaña J, Aronson M, Antoniazzi AP, Palmero EI, Mansfield P, van der Kolk LE, Cats A, van Dieren JM, Castellví-Bel S, Katona B, Karam R, Pereira PS, Benusiglio PR, Oliveira C

doi: 10.1136/gutjnl-2024-334601

Helicobacter Pylori

Anti-Parietal Cell Antibodies Show Differential Associations With Stomach Cancer by Site and Helicobacter pylori Status

Helicobacter

Jayasekara H, Bassett JK, Tang HH, Peng Y, Tsimiklis H, O'Reilly RL, Lynch BM, MacInnis RJ, Giles GG, Southey MC, Milne RL, Camargo MC

doi: 10.1111/hel.70093

Hepatology

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)

Hepatology

Nahon P, Ziol M, Pan L, Portal JJ, Oberti F, Aube C, Blanc JF, Trillaud H, Merle P, Rode A, Assenat E, Guiu B, Lequoy M, Cornelis F, Bouattour M, Talib Z, Tibi A, Zeng Q, Bouda Y, Ganne-Carrié N, Sutter O, Sutton A, Guyot E, Barget N, Zucman-Rossi J, Campani C, Bamba-Funck J, Calderaro J, Nault JC, Vicaut E, Seror O

doi: 10.1097/HEP.0000000000001764

Hepatology

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Lancet Gastroenterol Hepatol

Celsa C, Pennisi G, Tulone A, Ciancimino G, Vaccaro M, Pecorella F, Di Maria G, Enea M, Midiri F, Mantovani A, Targher G, Krag A, Rinella ME, Cammà C, Petta S

doi: 10.1016/S2468-1253(25)00188-8

HepatitisHepatology

Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-Associated Liver Disease

Clin Gastroenterol Hepatol

Torosian K, Díaz LA, Tesfai K, Wu W, Cooper KM, Devuni D, Mohamed K, Lim N, Rajan A, Cheung A, Wang K, Shroff H, Kwong A, Ajmera V

doi: 10.1016/j.cgh.2026.02.001

HepatitisHepatology

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Gut

Chang YP, Chen YC, Cheng PN, Fang YJ, Chen CY, Kao WY, Lin CL, Yang SS, Shih YL, Peng CY, Lee FJ, Tsai MC, Huang SC, Su TH, Tseng TC, Liu CJ, Chen PJ, Kao JH, Liu CH

doi: 10.1136/gutjnl-2025-337275

Hepatology

Longitudinal Changes in Cardiometabolic Risk Factors are Associated with Changes in Liver Stiffness in Adults with MASLD

J Hepatol

Dukewich M, Wilson LA, Dodge JL, Yuan L, Hameed B, Yates KP, Loomba R, Neuschwander-Tetri BA, Mack W, Terrault N, NASH Clinical Research Network

doi: 10.1016/j.jhep.2026.02.002

Gastrointestinal Cancer

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

Ann Oncol

Kato K, Ajani J, Doki Y, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, Hajbi FE, Di Bartolomeo M, Braghiroli MI, Holtved E, Makino T, Murphy MB, Zhang J, Sharma P, He B, Lei M, Matsumura Y, Kitagawa Y, Chau I

doi: 10.1016/j.annonc.2026.08.001

Gastrointestinal Cancer

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons

Adv Ther

Ajani JA, Wang K, Nikolaidis GF, Coaquira Castro J, Augusto Novis de Figueiredo M, Sun JM, Soulanis K, Tasoulas A, Zhan L

doi: 10.1007/s12325-025-03410-5

Related content

Hereditary diffuse gastric cancer spectrum associated with germline CTNNA1 loss of function revealed by clinical and molecular data from 351 carrier families and over 37 000 non-carrier controls

Anti-Parietal Cell Antibodies Show Differential Associations With Stomach Cancer by Site and Helicobacter pylori Status

Neoadjuvant and adjuvant nivolumab associated with irreversible electroporation in patients with BCLC a hepatocellular carcinoma and high risk of recurrence (NIVOLEP trial)

Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis

Cardiometabolic Risk Factors Impair Recompensation and Survival in Alcohol-Associated Liver Disease

Steatosis grade and cardiometabolic burden as determinants of hepatocellular carcinoma risk after hepatitis C cure in patients with metabolic dysfunction-associated steatotic liver disease

Longitudinal Changes in Cardiometabolic Risk Factors are Associated with Changes in Liver Stiffness in Adults with MASLD

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma: 5-year follow-up results from CheckMate 648

Comparative Efficacy and Safety of Tislelizumab in Second-Line Esophageal Squamous Cell Carcinoma: Systematic Literature Review and Simulated Treatment Comparisons